WAM
FENC icon

Wealthspire Advisors (Maryland)’s Fennec Pharmaceuticals FENC Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-9,500
Closed -$46K – 983
2019
Q1 		$46K Hold
9,500
– – ﹤0.01% 924
2018
Q4 		$61K Sell
9,500
-5,000
-34% -$34.9K 0.01% 772
2018
Q3 		$119K Hold
14,500
– – 0.01% 616
2018
Q2 		$151K Buy
+14,500
New +$172K 0.01% 553

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s FENC Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Fennec Pharmaceuticals (FENC) in Q2 2019, closing a stake of 9,500 shares — an estimated $46K sold.

Wealthspire Advisors (Maryland) first reported a position in FENC in Q2 2018 and held it in 4 quarters. The position peaked at $151K in Q2 2018. 30 funds tracked by Wall St. Rank hold FENC as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Fennec Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 9,500 Fennec Pharmaceuticals shares in Q2 2019, an estimated $46K.
  • Wealthspire Advisors (Maryland) first reported a position in Fennec Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Wealthspire Advisors (Maryland)'s Fennec Pharmaceuticals position peaked at $151K in Q2 2018.
  • 30 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.